ClinicalTrials.gg
Not yet recruitingNCT07859800Updated Nov 20, 2026

Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection

An interventional study of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography scan in Healthy Volunteer and Malaria, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 54 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Not applicable, Interventional, and Basic science

How we know

Updated Nov 20, 2026Start date movedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years to 54 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 112 studies in Malaria by National Institute of Allergy and Infectious Diseases (NIAID) — 9 open to participants now, 11 under way, none of them phase 3. Malaria · National Institute of Allergy and Infectious Diseases (NIAID).

Planned enrollment
49th of 63
45 · median 90
Started
2026
with 3 others
No phase
2 of 112
1 open now
Registered
111th of 112
by date

Among the 112 studies in Malaria by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 49th largest by planned enrollment of the 63 interventional ones that give a count, is one of 4 that started in 2026, is one of 2 with no phase, and was the 111th registered.

Malaria

1,187 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

9 of the 112 studies in Malaria by National Institute of Allergy and Infectious Diseases (NIAID) are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 54 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Malaria by National Institute of Allergy and Infectious Diseases (NIAID), or all of them as a file.
02

Study summary

Background:

Malaria is a serious disease caused by parasites spread by mosquitoes. To better diagnose and treat malaria, researchers need to learn more about where the parasites go when they enter a person's body. They want to see if they can locate the malaria parasites in the body using imaging scans.

Objective:

To learn whether imaging scans can locate parasites in people with malaria.

Eligibility:

Healthy people aged 18 to 54 years. They must be enrolled in protocol IRB001970 or IRB002627 for controlled malaria infection.

Design:

Participants will be screened. They will have blood drawn and a physical exam, including an abdominal exam to check the size of their spleen.

Participants for this study will have 2 or 3 positron emission tomography/computed tomography (PET/CT) scans: The first will be about 3 days before they are deliberately infected with malaria for a different study. The second will be about 13 days later, while they have the disease. The third scan is optional; it will be done about 3 and 1/2 weeks after the second scan.

For each scan, participants will receive a radioactive tracer called fluorodeoxyglucose (FDG). FDG will be injected through a tube inserted into a vein. They will lie on a table that slides through a doughnut-shaped machine. PET/CT uses x-rays to create images of the inside of the body.

All participants will have a follow-up visit about 3 and 1/2 weeks after the second scan. The blood draw and physical exam will be repeated. This visit may be combined with the third scan for those who choose it.

Read the detailed description

Study Description:

Participants who are enrolled in a Plasmodium vivax challenge model protocol at the NIH Clinical Center (CC) may be co-enrolled in this single-site study to undergo a 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET)/computed tomography (CT) scan of their chest, abdomen, and pelvis at baseline before controlled human malaria infection (CHMI) inoculation and again at the expected time of peak parasitemia. FDG uptake will be used to visualize organ-specific changes as a result of malaria infection. Other assessments will include inflammatory labs, signs of bone marrow activation, compete blood count (CBC), reticulocyte counts, and transcriptional analysis.

Objectives:

Primary Objectives:

-To measure changes in spleen standardized uptake value (SUV) from baseline in participants undergoing P. vivax CHMI using PET/CT imaging

Secondary Objectives:

  • Key secondary: To measure changes in organ-specific uptake of FDG from baseline in participants undergoing P. vivax CHMI using PET/CT imaging.
  • Explore the relationship between dyserythropoiesis, hematological abnormalities, and bone marrow/splenic involvement in acute P. vivax malaria.

Exploratory Objectives:

  • To better understand the biomass and sequestration of P. vivax malaria.
  • Improve understanding of timing and location of P. vivax sequestration in tissues.
  • Measure host and parasite factors that lead to organ-specific P. vivax disease.
  • Improve understanding of convalescent changes for expected or unexpected changes in organ size or SUV due to P. vivax after treatment

Endpoints:

Primary Endpoint:

-Percentage change in mean spleen SUV from baseline to post CHMI

Key Secondary Endpoints:

  • Percentage change in max spleen SUV
  • Percentage change in peak spleen SUV
  • Percentage change in spleen volume

Additional Secondary Endpoints:

  • Percentage change in liver volume
  • Percentage change in mean, max, and peak liver SUV
  • Percentage change in mean, max and peak bone marrow SUV
  • CBC with differential, reticulocyte count, and erythropoietin (EPO) at baseline, at the time of the second FDG-PET/CT, and at the end of the CHMI-related activities performed under the co-enrolled study.

Exploratory Endpoints:

  • Describe the relationship between parasitemia/gametocytemia and organ size changes and SUV on FDG-PET/CT with exploratory labs like Plasmodium vivax-specific LDH and others.
  • Other exploratory studies may include but are not limited to proteomic and metabolomic analysis, 10x genomics, and immunophenotyping using flow cytometry or immunohistochemistry (IHC) on peripheral blood mononuclear cells (PBMCs), cytokine levels.
  • Percentage change in organ volume and mean SUV after treatment compared to baseline and compared to the time of peak parasitemia
03

Conditions studied

  • Healthy Volunteer
  • Malaria

Browse trials for

Keywords

  • Imaging
  • PET/CT
  • Challenge Study
  • Spleen
04

Who can participate

Ages eligible
18 Years to 54 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Aged >=18 and \<=54 years.
  2. Able to provide .
  3. Co-enrolled in NIH protocol IRB001970, "Phase 1 study of induced blood-stage malaria in healthy malaria-naive adults to assess the safety and infectivity of Plasmodium vivax challenge agent and evaluate transmission in mosquito feeding assays" or IRB002627, "Phase 1/2 study of transmission-blocking vaccine Pvs230D1-EPA/Matrix-M in healthy malaria-naive adults using a Plasmodium vivax controlled human malaria infection model."
  4. Willing to allow long-term storage of study samples for future research.
  5. Individuals of must agree to use an acceptable method of from 1 month prior to the first FDG-PET/CT scan through the end of the study. Participants will also be expected to adhere to the strictest of the contraception

    requirements of any studies they are co-enrolled in. Acceptable methods of contraception include the following:

    • A barrier method (e.g., consistent condom use) combined with an oral contraceptive pill, hormonal patch, or ring.
    • Parenteral hormonal contraceptive implant or an intrauterine device.

    Participants who otherwise are not at risk of becoming pregnant, at the judgement of the investigator will not be required to use contraception. Such participants may include those:

    • Having undergone hysterectomy, bilateral oophorectomy, or bilateral fallopian tube ligation.
    • Having reached menopause (age >=45 years plus no menses for 12 consecutive months without an alternative medical cause).
    • Having exclusive same-sex relations or committed longstanding abstinence due to a serious life choice.
    • Having an exclusive male partner who has undergone vasectomy at least 4 months prior.
  6. Participants need to have established medical care with a primary care doctor or be willing to establish care in case medically relevant findings on their imaging require follow-up.

Exclusion criteria

EXCLUSION CRITERIA

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Pregnancy or lactation.
  2. History of splenectomy.
  3. History of diabetes or poorly controlled blood sugar, in the judgement of the investigators, would prevent completion of FDG-PET/CT scan.
  4. Currently undergoing therapy with drugs that, in the judgment of the investigators, may interfere with biodistribution of FDG (e.g., insulin that cannot be held or metformin that cannot be stopped for 48 hours prior to each FDG-PET/CT.).
  5. Any other finding that, in the judgment of the investigator, would interfere with, or serve as a to, protocol adherence, assessment of safety, or a participant s ability to give , or increase the risk of having an adverse outcome from

participating in the study.

Co-enrollment guidelines: Co-enrollment in other trials is restricted, other than enrollment on the LMIV CHMI trials described above and NIH protocol 17I0122, NIAID Centralized Sequencing Protocol. Study staff should be notified of co-enrollment on any other protocol as it may require the approval of the principal investigator.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Healthy Volunteers who are co-enrolled in a P. vivax CHMI study

    Healthy Volunteers are co-enrolled in a Plasmodium vivax challenge model protocol at the NIH Clinical Center.

    Diagnostic Test: 18F-fluorodeoxyglucose-positron emission tomography/computed tomography scan

Interventions

  • Diagnostic test18F-fluorodeoxyglucose-positron emission tomography/computed tomography scan

    Participants are co-enrolled in a Plasmodium vivax challenge model protocol at the NIH Clinical Center. These participants will undergo up to 3 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET)/computed tomography (CT) scans of their chest, abdomen, and pelvis. PET/CT scans will occur at baseline (before controlled human malaria infection (CHMI) inoculation), and at the expected time of peak parasitemia. Participants may have an optional 3rd PET/CT scan at day 34 after the CHMI inoculation. FDG uptake will be used to visualize organ-specific changes as a result of malaria infection.

06

What researchers measure

Primary outcomes

  1. To measure changes in spleen standardized uptake value (SUV) from baseline in participants undergoing P. vivax CHMI using PET/CT imaging

    Percentage change in mean spleen SUV from baseline to post-CHMI

    Time frame: 34 (+/- 5 days) days post CHMI Inoculation

Secondary outcomes

  1. To measure changes in organ specific uptake of FDG from baseline in participants undergoing P. vivax CHMI using PET/CT imaging

    Percentage change in max spleen SUV Percentage change in peak spleen SUVPercentage change in spleen volume Percentage change in liver volumePercentage change in liver SUVPercentage change in bone marrow SUV

    Time frame: 34 (+/- 5 days) days post CHMI Inoculation

  2. Explore the relationship between dyserythropoiesis, hematological abnormalities, and bone marrow/splenic involvement in acute P. vivax malaria.

    CBC with differential, reticulocyte count, and erythropoietin (EPO) at baseline, at the time of the second FDG-PET/CT, and at the end of the CHMI-related activities performed under the co-enrolled study.

    Time frame: 34 (+/- 5 days) days post CHMI Inoculation

07

Study locations

1 site
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
08

References and documents

Publications

  • Woodford J, Gillman A, Jenvey P, Roberts J, Woolley S, Barber BE, Fernandez M, Rose S, Thomas P, Anstey NM, McCarthy JS. Positron emission tomography and magnetic resonance imaging in experimental human malaria to identify organ-specific changes in morphology and glucose metabolism: A prospective cohort study. PLoS Med. 2021 May 26;18(5):e1003567. doi: 10.1371/journal.pmed.1003567. eCollection 2021 May. PubMed 34038421 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

32 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2030, 47 months later.

Of 96 non-industry interventional studies with no phase under Malaria, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 47 months is above that.

Counting every sponsor, half of 102 studies reached it within 23 months; a quarter within 8 and three quarters within 33.

Start moved 31 times since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, last on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2026
First posted
Oct 6, 2026
StartEst.
Nov 25, 2026was Oct 2026
Primary completionEst.
Nov 1, 2030
CompletionEst.
Nov 1, 2030
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 11, 2026→Nov 25, 2026
moved 31 times, Oct 7, 2026 – Nov 20, 2026
Registered
First appeared on the registry
Oct 6, 2026
Show all 32 updates
  1. Nov 20, 2026
    Start date Nov 24, 2026→Nov 25, 2026
  2. Nov 19, 2026
    Start date Nov 23, 2026→Nov 24, 2026
  3. Nov 18, 2026
    Start date Nov 22, 2026→Nov 23, 2026
  4. Nov 17, 2026
    Start date Nov 19, 2026→Nov 22, 2026
  5. Nov 16, 2026
    Start date Nov 18, 2026→Nov 19, 2026
  6. Nov 13, 2026
    Start date Nov 17, 2026→Nov 18, 2026
  7. Nov 12, 2026
    Start date Nov 15, 2026→Nov 17, 2026
  8. Nov 10, 2026
    Start date Nov 12, 2026→Nov 15, 2026
  9. Nov 9, 2026
    Start date Nov 11, 2026→Nov 12, 2026
  10. Nov 6, 2026
    Start date Nov 10, 2026→Nov 11, 2026
  11. Nov 5, 2026
    Start date Nov 9, 2026→Nov 10, 2026
  12. Nov 4, 2026
    Start date Nov 8, 2026→Nov 9, 2026
  13. Nov 3, 2026
    Start date Nov 5, 2026→Nov 8, 2026
  14. Nov 2, 2026
    Start date Nov 4, 2026→Nov 5, 2026
  15. Oct 30, 2026
    Start date Nov 3, 2026→Nov 4, 2026
  16. Oct 29, 2026
    Start date Nov 2, 2026→Nov 3, 2026
  17. Oct 28, 2026
    Start date Nov 1, 2026→Nov 2, 2026
  18. Oct 27, 2026
    Start date Oct 29, 2026→Nov 1, 2026
  19. Oct 26, 2026
    Start date Oct 28, 2026→Oct 29, 2026
  20. Oct 23, 2026
    Start date Oct 27, 2026→Oct 28, 2026
  21. Oct 22, 2026
    Start date Oct 26, 2026→Oct 27, 2026
  22. Oct 21, 2026
    Start date Oct 25, 2026→Oct 26, 2026
  23. Oct 20, 2026
    Start date Oct 22, 2026→Oct 25, 2026
  24. Oct 19, 2026
    Start date Oct 21, 2026→Oct 22, 2026
  25. Oct 16, 2026
    Start date Oct 20, 2026→Oct 21, 2026
  26. Oct 15, 2026
    Start date Oct 19, 2026→Oct 20, 2026
  27. Oct 14, 2026
    Start date Oct 18, 2026→Oct 19, 2026
  28. Oct 13, 2026
    Start date Oct 14, 2026→Oct 18, 2026
    + 1 other change: verification date
  29. Oct 9, 2026
    Start date Oct 13, 2026→Oct 14, 2026
  30. Oct 8, 2026
    Start date Oct 12, 2026→Oct 13, 2026
  31. Oct 7, 2026
    Start date Oct 11, 2026→Oct 12, 2026
  32. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07859800
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Nov 25, 2026 (estimated)
Primary completion
Nov 1, 2030 (estimated)
Completion
Nov 1, 2030 (estimated)
Last update
Nov 20, 2026

Study contacts

Shanan R Immel, M.D.
Contact
shanan.immel@nih.gov
(240) 220-0650
Shanan R Immel, M.D.
principal investigator · National Institute of Allergy and Infectious Diseases (NIAID)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion